1xbet 리뷰., Ltd.

1xbet 리뷰., Ltd. announces that it has received regulatory approval in Japan for an orally-disintegrating-dose (OD) form of REXULTI^® (brexpiprazole) tablets.

REXULTI^®OD 0.5 mg, 1 mg, and 2 mg tablets will now become available in addition to the already available regular tablets in 1mg and 2mg doses. REXULTI^®OD Tablets are a dose 1xbet 리뷰m that quickly disintegrate in the oral cavity so that it is easy to take 1xbet 리뷰 patients who cannot take the tablet due to difficulty in swallowing.

Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at 5-HT_1Aand dopamine D₂receptors, and an antagonist at 5-HT_2Aand noradrenaline alpha_1B/2Creceptors.

It received manufacturing and marketing approval 1xbet 리뷰 for the indication of schizophrenia in 2018.